Fresh debate over PSA screening 23 Mar 2012 0 comments Routine PSA screening can significantly reduce deaths from prostate cancer, fresh research suggests, but the RACGP remains unconvinced the evidence is strong enough.
Chest x-ray doesn’t reduce lung cancer deaths 28 Oct 2011 0 comments Annual screening with chest radiograph does not reduce lung cancer mortality, new research confirms, but experts remain optimistic about CT screening.
Gender a factor in colon screening 7 Oct 2011 0 comments Bowel cancer screening eligibility should be based on gender as well as age, European researchers say.
Informed consent a balancing act 23 Sep 2011 0 comments Patients want to be informed about trainees participating in their procedure, but that information significatly reduces their willingness to consent.
Post-treatment support lacking: study 16 Sep 2011 0 comments Childhood cancer survivors and their families feel they are not given sufficient information on challenges they may face post-treatment, Australian research finds.
Prognostic tool accurately predicts survival 26 Aug 2011 0 comments New prognostic tools for patients with advanced cancer in palliative care can reliably predict survival times, researchers find.
Rural breast cancer patients face long delays 19 Aug 2011 0 comments Rural breast cancer patients could be up to 7% more likely to die compared with those living in urban areas, Australian researchers find.
Post-hepatectomy antiviral therapy improves survival 1 Jul 2011 0 comments Antiviral therapy after hepatectomy improves survival in patients with hepatitis B-related hepatocellular carcinoma, research suggests.
Age no barrier to cancer research: study 13 May 2011 0 comments Age and frailty need not be barriers to cancer research, as using low-dose chemotherapy regimens makes it possible for older patients with advanced colorectal cancer to be involved in clinical
Call to fund gene testing for lung cancer patients 15 Apr 2011 0 comments An Australian expert has called for EGFR mutation testing to be funded in patients with advanced non-small-cell lung cancer to determine first-line treatment.